首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice
【2h】

Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice

机译:正确折叠的恶性疟原虫Pfs48 / 45蛋白引发小鼠疟疾传播阻断免疫

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malaria kills >1 million people each year, in particular in sub-Saharan Africa. Although asexual forms are directly responsible for disease and death, sexual stages account for the transmission of Plasmodium parasites from human to the mosquito vector and therefore the spread of the parasite in the population. Development of a malaria vaccine is urgently needed to reduce morbidity and mortality. Vaccines against sexual stages of Plasmodium falciparum are meant to decrease the force of transmission and consequently reduce malaria burden. Pfs48/45 is specifically expressed in sexual stages and is a well established transmission-blocking (TB) vaccine candidate. However, production of correctly folded recombinant Pfs48/45 protein with display of its TB epitopes has been a major challenge. Here, we show the production of a properly folded Pfs48/45 C-terminal fragment by simultaneous coexpression with four periplasmic folding catalysts in Escherichia coli. This C-terminal fragment fused to maltose binding protein was produced at medium scale with >90% purity and a stability over at least a 9-month period. It induces uniform and high antibody titers in mice and elicits functional TB antibodies in standard membrane feeding assays in 90% of the immunized mice. Our data provide a clear perspective on the clinical development of a Pfs48/45-based TB malaria vaccine.
机译:疟疾每年造成超过100万人死亡,特别是在撒哈拉以南非洲。尽管无性形式直接导致疾病和死亡,但性生活阶段是疟原虫寄生虫从人到蚊媒的传播媒介,因此也导致了寄生虫在人群中的传播。迫切需要开发一种疟疾疫苗以降低发病率和死亡率。针对恶性疟原虫性阶段的疫苗旨在减少传播力,从而减少疟疾负担。 Pfs48 / 45在性生活阶段特异性表达,是公认的传播阻断(TB)疫苗候选者。然而,具有其TB表位的展示的正确折叠的重组Pfs48 / 45蛋白的生产一直是主要挑战。在这里,我们显示了通过与大肠杆菌中的四种周质折叠催化剂同时共表达而适当折叠的Pfs48 / 45 C端片段的产生。该融合至麦芽糖结合蛋白的C末端片段以中等规模产生,纯度> 90%,并且在至少9个月的时间内具有稳定性。它在90%的免疫小鼠中通过标准的膜喂养试验在小鼠中诱导均匀且高的抗体滴度,并引发功能性TB抗体。我们的数据为基于Pfs48 / 45的TB疟疾疫苗的临床开发提供了清晰的视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号